News

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.

Adam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.

RMC-6236 was safe and tolerable in patients with mutant solid tumors harboring KRAS G12X mutations across various cancer types.

The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.

Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.

Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.

In this article, John M. Burke, MD, discusses the high prices of prescription drugs and the new law that allows the government to negotiate drug prices with manufacturers.

Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.

Maintenance therapy with lenalidomide and rituximab is safe and feasible for the treatment of patients with mantle cell lymphoma.

The first group of patients in a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor type 2 has finished dosing.

In an interview with Targeted Oncology, Q3 2023 Oncology Icons honoree, Daniel Efiom-Ekaha, MD, FACP, discussed his years of experience in community practice.

Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.

The FDA has approved capivasertib with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.

Michael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.

Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.

In an interview with Targeted Oncology, Maen Hussein, MD, a Q3 2023 Oncology Icons honoree, discusses his path to the community oncology setting and highlights upcoming trends in oncology he feels will improve patient outcomes.

Repotrectinib is now an FDA-approved option for patients with ROS1- positive advanced non-small cell lung cancer.

In a phase 3 trial, concurrently administered durvalumab and platinum-based chemoradiotherapy did not increase progression-free survival in stage III unresectable non–small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

SIRPant-M has been granted orphan drug designation by the FDA for patients with T-cell lymphoma.

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

This award celebrates the outstanding achievements of professionals who have significantly impacted the oncology landscape.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Following the FDA’s denial of a de novo classification request of ProSense, citing concerns about the choice of comparator group used in the ICE3 trial, IceCure is working to identify a more representative comparator group.

Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

The fast track designation granted to SONALA-001 in combination with the INSIGHTEC Exablate 4000 Type-2 Device from the FDA is for the treatment of patients with diffuse intrinsic pontine glioma.